Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.

Breast cancer research and treatment - 1 Aug 2016

Brentnall Adam R, Cuzick Jack, Byers Helen, Segal Corrinne, Reuter Caroline, Detre Simone, Sestak Ivana, Howell Anthony, Powles Trevor J, Newman William G, Dowsett Mitchell

Abstract excerpt

A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive most anti-cancer benefit from selective oestrogen receptor modulator (SERM) therapy. In this article, we further examine this question using blood samples from two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cathepsins

Share to Logistic Models

Share to Odds Ratio

Share to Proteins

Share to Randomized Controlled Trials as Topic

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 27400912
DOI: 10.1007/s10549-016-3885-x
PMCID: PMC4977422

Genes

CTSO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.PMID 27400912Read ↗

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.Semantic proximity Read ↗

Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.Semantic proximity Read ↗

SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.Semantic proximity Read ↗

Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish populationSemantic proximity Read ↗

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Semantic proximity Read ↗

Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.Semantic proximity Read ↗

Ovarian cancer risk according to circulating zinc and copper concentrations: A meta-analysis and Mendelian randomization study.Semantic proximity Read ↗

A commentary on Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.